ABBV RetestABBV has retest previous support levels and remounted since. This looks bullish back to the previous high around 109-110 range. A break below the moving average will show lack of strength and i'll exit the trade.
ABBV trade ideas
Abbvie short term bullish trade idea
Abbvie has progressed towards its previous resistance and looks to be testing its last high. I am planning on watching for a bullish move that breaks this resistance and will hold the trade until the RSI trend line is broken or until the Fibonacci take profit zones have been reached. Dont be surprised if it takes a day or two to develop but the time frame of occurrence I expect will be between now and the end of the week.
Updated $ABBV Bearish Swing Trade PlanGreen Line - Entry Target
Red Line - Exit Target
Pink Line - Stop-Loss
Highly suggest using Google to Search "Transparent Traders" if you're trying to get to the next level.
Transparent Traders exists to solve the critical issues facing our traders, both large and small. Our unique approach is not only what differentiates us, but also what makes us successful.
Our advanced Blackbox uses custom algorithms & predictive A.I. to locate the most accurate day or swing trades for the best chance of success.
$ABBV Bearish Swing Trade PlanGreen Line - Entry Target
Red Line - Exit Target
Pink Line - Stop-Loss
Highly suggest using Google to Search "Transparent Traders" if you're trying to get to the next level.
Transparent Traders exists to solve the critical issues facing our traders, both large and small. Our unique approach is not only what differentiates us, but also what makes us successful.
Our advanced Blackbox uses custom algorithms & predictive A.I. to locate the most accurate day or swing trades for the best chance of success.
$ABBV posted a less than expected earningsPEAD projected a negative outlook for $ABBV after the later posted less than expected earnings with the price currently trading close to the upper boundary.
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
ABBV Long, DemandDown below a support line
Touched Demand zone.
Entry 80
Stop 78
Target 88
reward:risk=4:1
Stock traders better wait.
Earning date 10/30 7AM
I am not a PRO trader. I need few months to practice trading strategies.
If you like this idea, please use SIM/Demo account to try it, until my trading plans get high winning rate.
ABBV, is it a buy right now?☝️ Losing patent protection for a top-selling blockbuster drug is a big setback for any pharmaceutical company, but this can also give us great opportunities. They have done a great strategic-movement by acquiring Allergan.
It's down 18% from last July 17 high, earnings are close. I believe, yes, it's a good moment to START doing COST-AVERAGE.
The price is almost getting closer to the 50% Fibonacci (from last Mar 20). I'm protecting an optimistic retracement to 127% (at $108.58) Fibonacci (drawing from today), very close to the analyst's current average price target at $109.21. A more conservative take profit would be at $95.
- P/E GAAP (TTM) of 18.63, sector media of 35.57 👍
- Forward P/E of 6.94 👍
- PEG GAAP (TTM) of 0.29, sector media of 0.88 👍
- EV / EBITDA (TTM) of 13.76 in a sector media of 19.29 👍
- Debt / Eq of 5.4 😐
- Dividend yield of 5.60% 😍
Nothing else to say, it's a great company, with great dividends. I'm in! 👌
This isn't trading advice. I've no idea what I'm talking about 😉.
Trade with caution! 🚨
Have a good day! 🤟
$ABBV AbbVie Inc. - Double Bottom, Bullish Options Activity$ABBV AbbVie Inc. - Looking like a possible double bottom just under $86 after about a two month bear move.
Expecting a strong move in the near term once this can clear the 200d ema (currently ~$89.00). Note: earnings upcoming, expected 10/30/20.
Huge Bullish Options Flow in this name today:
$122M in January'21 calls traded today (varying strikes, most deep ITM), on avg 8x OI - 58k contracts in total. Definitely looks like a large hedge fund trade.
Positive fundamental news out today (possible driver of bullish options activity):
"The National Institutes of Health said is running a mid-stage clinical trial evaluating a monoclonal antibody it developed with the privately held Boehringer Ingelheim in combination with remdesivir as a COVID-19 treatment."
Source: MarketWatch.com -> www.marketwatch.com
Medium term target: $107 by year-end
Note: This is NOT investment advice.
